Which of the following content, programs, or services would you like to see from pharmaceutical companies over the next 2-3 months?

- Enhanced compliance and adherence programs for patients
- Enhanced patient assistance programs (co-pay, financial support)
- Increased use of digital tools to interact with sales reps
- Increased use of digital tools to interact with MSL (medical science liaisons)
- Additional content in social media for consumers
- Additional content in social media for healthcare professionals

What are expected near-term impacts due to current physical distancing requirements?

- Patient backlog due to canceled/postponed appointments
- Temperature checks required before appointment starts
- Creating a low/no-touch registration and waiting room experience
- Increased telehealth/virtual visits
- Increased house calls

How likely are you to increase the use of telehealth/virtual appointments even after physical distancing due to COVID-19 is lifted?

- Not at all likely
- Somewhat likely
- Likely
- Very likely
- Extremely likely
- NA

How would you rate perceived patient satisfaction with tele-health/virtual visits as a proxy for in-person appointments?

- Patient seems very dissatisfied
- Patient seems somewhat dissatisfied
- Patient seems satisfied
- Patient seems somewhat satisfied
- Patient seems very satisfied
- NA

How would you describe your satisfactions with tele-health patient visits as a proxy for live appointments?

- Very dissatisfied
- Somewhat dissatisfied
- Satisfied
- Somewhat satisfied
- Very satisfied
- Other
- NA

Have you supplemented tele-health/virtual appointments for some or all of your patient interactions due to COVID-19?

NA

What is your level of interest in programs or services when seeking clinical information related to pharmaceutical products?

- Physician portal from an individual pharma company
- Portal with clinical information from all pharma companies
- MSL chatbots for physicians (provided by pharma company)
- Email content sent to me directly from pharma company
- Enhanced content in social media from a pharma company
- Video chats or calls with the pharma company
- No interest
- Other
- NA

Estimate the allocation of information you will receive in the future by source (in person vs. digital)

- Traditional (in person)
- Digital
- N/A

Have you been actively seeking information to fill the gap created by limited pharma sales rep access?

- Yes
- No
- NA

What are your concerns, if any, about the current reduction in pharma sales rep access?

- Rx Sample Access
- Updates in Drug/Rx Information
- Updates in Rx Clinical Trial Results
- Professional Education
- No Concerns About the Current Reduction in Pharma Rep Access
- NA

In a post-COVID-19 environment, do you foresee a change/limitation in pharma sales rep access?

- No change - a return to pre-COVID-19 "normal" in the future
- Some change - mild limitations to access in the future
- Significant change - major limitations to access in the future
- Complete change - sales rep access will not restart in the future
- NA

Which of the following methods have you used to replace the in-person pharma sales rep visit?

- Video calls with the same pharma sales rep
- Phone call with the same pharma sales rep
- Direct emails from the same pharma sales rep
- Video calls with another pharma sales rep from the company
- Phone call with another pharma sales rep from the company
- Direct emails from another pharma sales rep from the company
- No contact with any pharma sales reps has occurred
- Other
- NA

Has your interaction with pharma sales reps decreased as a result of COVID-19?

- Yes
- No
- NA